Analysis of the efficacy and safety of ceftazidime avibactam sodium for injection alone in the treatment of pneumonia caused by carbapenem-resistant Klebsiella pneumoniae infection

Li Yinhua; Niu Jianxing; Li Xiyuan

doi:10.3760/j.issn.1673-4777.2025.04.011

Abstract：Objective To investigate the efficacy and safety of ceftazidime avibactam sodium for injection in the treatment of pneumonia caused by carbapenem-resistant Klebsiella pneumoniae(CRKP)infection.Methods Clinical data of 38 patients with pneumonia caused by CRKP admitted to the intensive care unit of Aviation General Hospital from January 1,2022 to October 31,2024 were retrospectively analyzed.According to different treatment regimens,they were divided into monotherapy group(16 cases,treated with intravenous infusion of ceftazidime avibactam sodium for injection on the basis of conventional treatment)and combined treat-ment group(22 cases,treated with intravenous infusion of ceftazidime avibactam sodium for injection combined with meropenem or tigecycline or epiracycline or polymyxin B on the basis of conventional treatment).Relevant data were collected,and the clinical treatment effects(clinical effective rate,microbial cure rate,bacterial clearance time,body temperature normalization time,inflammatory index changes,28-day mortality,total hospital mortality)and adverse reactions were compared between the two groups.Results The acute physiology and chronic health evaluation Ⅱ score of the combined treatment group was slightly higher than that of the monotherapy group(P＜0.05).There were no significant differences in clinical efficacy,28-day mortality and total in-hospital mortality between the two groups(all P＞0.05).The microbial cure rate of the combined treatment group was slightly higher than that of the monotherapy group,and the bacterial clearance time and body temperature normali-zation time were slightly shorter than those of the monotherapy group,but the differences were not statistically significant(all P＞0.05).There was no significant difference in white blood cell count,procalcitonin and C-reactive protein levels between the two groups before and after treatment(all P＞0.05).The incidence of kidney injury,liver injury and gastrointestinal symptoms in the combined treatment group was slightly higher than that in the monotherapy group[13.6％(3/22)vs 12.5％(2/16),18.2％(4/22)vs 12.5％(2/16),18.2％(4/22)vs 12.5％(2/16)],but the differences were not statistically significant(all P＞0.05).Conclusion For patients with pneumonia caused by CRKP infection,there is no significant difference in the overall efficacy between ceftazi-dime avibactam sodium injection monotherapy and combination therapy with other drugs,and there is no significant difference in adverse reactions.